[ad_1]
A volunteer in Brazil who participated in the tests of the coronavirus vaccine developed by AstraZeneca and the University of Oxford has died. This was announced by the National Health Surveillance Agency (Anvisa) of the country, cited by Uol. According to the agency, after an investigation, it was decided that the trials should continue because “there were no concerns about the safety of the clinical trial.”
The president of the Irbm research center in Pomezia Piero Di Lorenzo, which is collaborating with the University of Oxford for the development of a Covid 19 vaccine for Astra Zeneca, confirms the availability of the first doses for December, already announced in recent days by Prime Minister Giuseppe Conte. According to Di Lorenzo “if there are no sudden problems – he said during an interview with the Financial Lounge site – it is reasonable to think that the clinical trial phase may be complete by the end of November or beginning of December”. “After phase 3 – he continued – the balloon goes to EMA (the European Medicines Agency, ed) for possible validation”, which normally takes up to 12 months. “But these are not normal times,” explains Di Lorenzo, who remembers how the validation process has already begun.
[ad_2]
